FDA Clearance Tracker · DEN240062
Minder System
Last checked: Nov 20, 2026Latest source record: Apr 17, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Apr 17, 2025
De Novo granted
Time to decision
181 days
Received Oct 18, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN240062
- Device name
- Minder System
- Applicant
- Epi-Minder Pty, Ltd.
- Applicant location
- Melbourne, AU
- Received
- Oct 18, 2024
- Decided
- Apr 17, 2025
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.1360
- Specialty
- Neurology & Neurosurgery
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN240062
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Epi-Minder Pty, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Minder® System510(k)
K262318 · Decided Oct 29, 2026 · 113 days after receipt
Device type: Sub-Scalp Implanted Electroencephalogram System For Remote Patient Monitoring (SEM) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.